Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited has announced a significant convertible bond offering to raise A$600 million, set to mature in 2029. This financial move is intended to accelerate the company’s clinical development programs, support potential strategic mergers and acquisitions, and enhance its global manufacturing capabilities. The offering will be listed on the Singapore Exchange and is backed by J.P. Morgan Securities plc as the sole manager.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.